4lp0 - Revision history

OCA at 12:21, 1 March 2024

2024-03-01T12:21:04Z

←Older revision		Revision as of 12:21, 1 March 2024
Line 4:		Line 4:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4lp0]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Streptococcus_pneumoniae_R6 Streptococcus pneumoniae R6]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4LP0 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4LP0 FirstGlance]. <br>		<table><tr><td colspan='2'>[[4lp0]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Streptococcus_pneumoniae_R6 Streptococcus pneumoniae R6]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4LP0 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4LP0 FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=1YM:6-[(ETHYLCARBAMOYL)AMINO]-4-[4-(TRIFLUOROMETHYL)-1,3-THIAZOL-2-YL]-3,3-BIPYRIDINE-5-CARBOXYLIC+ACID'>1YM</scene></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 1.95Å</td></tr>
		+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=1YM:6-[(ETHYLCARBAMOYL)AMINO]-4-[4-(TRIFLUOROMETHYL)-1,3-THIAZOL-2-YL]-3,3-BIPYRIDINE-5-CARBOXYLIC+ACID'>1YM</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4lp0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4lp0 OCA], [https://pdbe.org/4lp0 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4lp0 RCSB], [https://www.ebi.ac.uk/pdbsum/4lp0 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4lp0 ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4lp0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4lp0 OCA], [https://pdbe.org/4lp0 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4lp0 RCSB], [https://www.ebi.ac.uk/pdbsum/4lp0 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4lp0 ProSAT]</span></td></tr>
	</table>		</table>
	== Function ==		== Function ==
	[https://www.uniprot.org/uniprot/Q8DQB5_STRR6 Q8DQB5_STRR6]		[https://www.uniprot.org/uniprot/Q8DQB5_STRR6 Q8DQB5_STRR6]
-	<div style="background-color:#fffaf0;">
-	== Publication Abstract from PubMed ==
-	The discovery and optimization of a new class of bacterial topoisomerase (DNA gyrase and topoisomerase IV) inhibitors binding in the ATP domain are described. A fragment molecule, 1-ethyl-3-(2-pyridyl)urea, provided sufficiently potent enzyme inhibition (32 muM) to prompt further analogue work. Acids and acid isosteres were incorporated at the 5-pyridyl position of this fragment, bridging to a key asparagine residue, improving enzyme inhibition, and leading to measurable antibacterial activity. A CF3-thiazole substituent at the 4-pyridyl position improved inhibitory potency due to a favorable lipophilic interaction. Promising antibacterial activity was seen versus the Gram-positive pathogens Staphylococcus aureus and Streptococcus pneumoniae and the Gram-negative pathogens Haemophilus influenzae and Moraxella catarrhalis . Precursor metabolite incorporation and mutant analysis studies support the mode-of-action, blockage of DNA synthesis by dual target topoisomerase inhibition. Compound 35 was efficacious in a mouse S. aureus disease model, where a 4.5-log reduction in colony forming units versus control was demonstrated.
-
-	Fragment-to-Hit-to-Lead Discovery of a Novel Pyridylurea Scaffold of ATP Competitive Dual Targeting Type II Topoisomerase Inhibiting Antibacterial Agents.,Basarab GS, Manchester JI, Bist S, Boriack-Sjodin PA, Dangel B, Illingworth R, Sherer BA, Sriram S, Uria-Nickelsen M, Eakin AE J Med Chem. 2013 Oct 29. PMID:24098982<ref>PMID:24098982</ref>
-
-	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	</div>
-	<div class="pdbe-citations 4lp0" style="background-color:#fffaf0;"></div>

	==See Also==		==See Also==
	*[[Topoisomerase 3D structures\|Topoisomerase 3D structures]]		*[[Topoisomerase 3D structures\|Topoisomerase 3D structures]]
-	== References ==
-	<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>

OCA at 11:16, 14 December 2022

2022-12-14T11:16:47Z

←Older revision		Revision as of 11:16, 14 December 2022
Line 1:		Line 1:

	==Crystal structure of a topoisomerase ATP inhibitor==		==Crystal structure of a topoisomerase ATP inhibitor==
-	<StructureSection load='4lp0' size='340' side='right' caption='[[4lp0]], [[Resolution\|resolution]] 1.95Å' scene=''>	+	<StructureSection load='4lp0' size='340' side='right'caption='[[4lp0]], [[Resolution\|resolution]] 1.95Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[4lp0]] is a 1 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Strr6 Strr6~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4LP0 OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4LP0 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[4lp0]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Streptococcus_pneumoniae_R6 Streptococcus pneumoniae R6]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4LP0 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4LP0 FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=1YM:6-[(ETHYLCARBAMOYL)AMINO]-4-[4-(TRIFLUOROMETHYL)-1,3-THIAZOL-2-YL]-3,3-BIPYRIDINE-5-CARBOXYLIC+ACID'>1YM</scene>~~</td></tr>~~	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=1YM:6-[(ETHYLCARBAMOYL)AMINO]-4-[4-(TRIFLUOROMETHYL)-1,3-THIAZOL-2-YL]-3,3-BIPYRIDINE-5-CARBOXYLIC+ACID'>1YM</scene></td></tr>
-	~~<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4lpb\|4lpb]]</td></tr>~~	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4lp0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4lp0 OCA], [https://pdbe.org/4lp0 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4lp0 RCSB], [https://www.ebi.ac.uk/pdbsum/4lp0 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4lp0 ProSAT]</span></td></tr>
-	~~<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">parE, spr0756 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=171101 STRR6])~~</td></tr>	+
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4lp0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4lp0 OCA], [~~http~~://pdbe.org/4lp0 PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=4lp0 RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/4lp0 PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=4lp0 ProSAT]</span></td></tr>	+
	</table>		</table>
		+	== Function ==
		+	[https://www.uniprot.org/uniprot/Q8DQB5_STRR6 Q8DQB5_STRR6]
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 20:		Line 20:

	==See Also==		==See Also==
-	*[[Topoisomerase\|Topoisomerase]]	+	*[[Topoisomerase 3D structures\|Topoisomerase 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Strr6~~]]	+	[[Category: Large Structures]]
-	[[Category: Basarab~~, G S~~]]	+	[[Category: Streptococcus pneumoniae R6]]
-	[[Category: Bist, S]]	+	[[Category: Basarab GS]]
-	[[Category: Boriack-Sjodin~~, P A~~]]	+	[[Category: Bist S]]
-	[[Category: Dangel, B]]	+	[[Category: Boriack-Sjodin PA]]
-	[[Category: Eakin~~, A E~~]]	+	[[Category: Dangel B]]
-	[[Category: Illingsworth, R]]	+	[[Category: Eakin AE]]
-	[[Category: Manchester~~, J I~~]]	+	[[Category: Illingsworth R]]
-	[[Category: Sherer~~, B A~~]]	+	[[Category: Manchester JI]]
-	[[Category: Sriram, S]]	+	[[Category: Sherer BA]]
-	[[Category: Uria-Nickelsen, M]]	+	[[Category: Sriram S]]
-	~~[[Category: Antimicrobial]]~~	+	[[Category: Uria-Nickelsen M]]
-	~~[[Category: Atp binding]]~~	+
-	~~[[Category: Atpase domain]]~~	+
-	~~[[Category: Isomerase-isomerase inhibitor complex]]~~	+
-	~~[[Category: Protein-inhibitor complex]]~~	+
-	~~[[Category: Structure-based drug design]]~~	+
-	~~[[Category: Virtual screen~~]]	+

OCA at 18:16, 11 August 2016

2016-08-11T18:16:25Z

←Older revision		Revision as of 18:16, 11 August 2016
Line 1:		Line 1:
		+
	==Crystal structure of a topoisomerase ATP inhibitor==		==Crystal structure of a topoisomerase ATP inhibitor==
	<StructureSection load='4lp0' size='340' side='right' caption='[[4lp0]], [[Resolution\|resolution]] 1.95Å' scene=''>		<StructureSection load='4lp0' size='340' side='right' caption='[[4lp0]], [[Resolution\|resolution]] 1.95Å' scene=''>
Line 6:		Line 7:
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4lpb\|4lpb]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4lpb\|4lpb]]</td></tr>
	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">parE, spr0756 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=171101 STRR6])</td></tr>		<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">parE, spr0756 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=171101 STRR6])</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4lp0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4lp0 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4lp0 RCSB], [http://www.ebi.ac.uk/pdbsum/4lp0 PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4lp0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4lp0 OCA], [http://pdbe.org/4lp0 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4lp0 RCSB], [http://www.ebi.ac.uk/pdbsum/4lp0 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4lp0 ProSAT]</span></td></tr>
	</table>		</table>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
Line 16:		Line 17:
	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>		From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
	</div>		</div>
		+	<div class="pdbe-citations 4lp0" style="background-color:#fffaf0;"></div>

	==See Also==		==See Also==

OCA at 08:59, 5 January 2015

2015-01-05T08:59:06Z

←Older revision		Revision as of 08:59, 5 January 2015
Line 1:		Line 1:
-	~~{{STRUCTURE_4lp0\| PDB~~=4lp0 \| ~~SCENE~~= }}	+	==Crystal structure of a topoisomerase ATP inhibitor==
-	===~~Crystal~~ structure of a ~~topoisomerase ATP inhibitor~~===	+	<StructureSection load='4lp0' size='340' side='right' caption='[[4lp0]], [[Resolution\|resolution]] 1.95Å' scene=''>
-	~~{{ABSTRACT_PUBMED_24098982}}~~	+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[4lp0]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Strr6 Strr6]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4LP0 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4LP0 FirstGlance]. <br>
		+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=1YM:6-[(ETHYLCARBAMOYL)AMINO]-4-[4-(TRIFLUOROMETHYL)-1,3-THIAZOL-2-YL]-3,3-BIPYRIDINE-5-CARBOXYLIC+ACID'>1YM</scene></td></tr>
		+	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4lpb\|4lpb]]</td></tr>
		+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">parE, spr0756 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=171101 STRR6])</td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4lp0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4lp0 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4lp0 RCSB], [http://www.ebi.ac.uk/pdbsum/4lp0 PDBsum]</span></td></tr>
		+	</table>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	The discovery and optimization of a new class of bacterial topoisomerase (DNA gyrase and topoisomerase IV) inhibitors binding in the ATP domain are described. A fragment molecule, 1-ethyl-3-(2-pyridyl)urea, provided sufficiently potent enzyme inhibition (32 muM) to prompt further analogue work. Acids and acid isosteres were incorporated at the 5-pyridyl position of this fragment, bridging to a key asparagine residue, improving enzyme inhibition, and leading to measurable antibacterial activity. A CF3-thiazole substituent at the 4-pyridyl position improved inhibitory potency due to a favorable lipophilic interaction. Promising antibacterial activity was seen versus the Gram-positive pathogens Staphylococcus aureus and Streptococcus pneumoniae and the Gram-negative pathogens Haemophilus influenzae and Moraxella catarrhalis . Precursor metabolite incorporation and mutant analysis studies support the mode-of-action, blockage of DNA synthesis by dual target topoisomerase inhibition. Compound 35 was efficacious in a mouse S. aureus disease model, where a 4.5-log reduction in colony forming units versus control was demonstrated.

-	~~==About this Structure==~~	+	Fragment-to-Hit-to-Lead Discovery of a Novel Pyridylurea Scaffold of ATP Competitive Dual Targeting Type II Topoisomerase Inhibiting Antibacterial Agents.,Basarab GS, Manchester JI, Bist S, Boriack-Sjodin PA, Dangel B, Illingworth R, Sherer BA, Sriram S, Uria-Nickelsen M, Eakin AE J Med Chem. 2013 Oct 29. PMID:24098982<ref>PMID:24098982</ref>
-	~~[[4lp0]] is~~ a ~~1 chain structure with sequence from [http://en~~.~~wikipedia~~.~~org/wiki/Strr6 Strr6]~~. ~~Full crystallographic information is available from [http~~:/~~/oca.weizmann.ac.il/oca-bin/ocashort?id=4LP0 OCA].~~	+

-	==~~Reference~~==	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	~~<ref group~~=~~"xtra">PMID:024098982</ref>~~<references ~~group="xtra"~~/><~~references~~/>	+	</div>
		+
		+	==See Also==
		+	*[[Topoisomerase\|Topoisomerase]]
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
	[[Category: Strr6]]		[[Category: Strr6]]
-	[[Category: Basarab, G S.]]	+	[[Category: Basarab, G S]]
-	[[Category: Bist, S.]]	+	[[Category: Bist, S]]
-	[[Category: Boriack-Sjodin, P A.]]	+	[[Category: Boriack-Sjodin, P A]]
-	[[Category: Dangel, B.]]	+	[[Category: Dangel, B]]
-	[[Category: Eakin, A E.]]	+	[[Category: Eakin, A E]]
-	[[Category: Illingsworth, R.]]	+	[[Category: Illingsworth, R]]
-	[[Category: Manchester, J I.]]	+	[[Category: Manchester, J I]]
-	[[Category: Sherer, B A.]]	+	[[Category: Sherer, B A]]
-	[[Category: Sriram, S.]]	+	[[Category: Sriram, S]]
-	[[Category: Uria-Nickelsen, M.]]	+	[[Category: Uria-Nickelsen, M]]
	[[Category: Antimicrobial]]		[[Category: Antimicrobial]]
	[[Category: Atp binding]]		[[Category: Atp binding]]

OCA at 06:54, 15 January 2014

2014-01-15T06:54:38Z

←Older revision		Revision as of 06:54, 15 January 2014
Line 4:		Line 4:

	==About this Structure==		==About this Structure==
-	[[4lp0]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4LP0 OCA].	+	[[4lp0]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Strr6 Strr6]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4LP0 OCA].

	==Reference==		==Reference==
	<ref group="xtra">PMID:024098982</ref><references group="xtra"/><references/>		<ref group="xtra">PMID:024098982</ref><references group="xtra"/><references/>
		+	[[Category: Strr6]]
	[[Category: Basarab, G S.]]		[[Category: Basarab, G S.]]
	[[Category: Bist, S.]]		[[Category: Bist, S.]]

OCA at 08:19, 13 November 2013

2013-11-13T08:19:26Z

←Older revision		Revision as of 08:19, 13 November 2013
Line 1:		Line 1:
-	~~'''Unreleased~~ structure~~'''~~	+	{{STRUCTURE_4lp0\| PDB=4lp0 \| SCENE= }}
		+	===Crystal structure of a topoisomerase ATP inhibitor===
		+	{{ABSTRACT_PUBMED_24098982}}

-	~~The entry~~ 4lp0 is ~~ON HOLD until sometime in the future~~	+	==About this Structure==
		+	[[4lp0]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4LP0 OCA].

-	~~Authors~~: Basarab, G.S.~~, Manchester, J.I.,~~ Bist, S., Boriack-Sjodin, P.A., Dangel, B., Illingsworth, R., ~~Uria-Nickelsen, M~~., Sherer, B.A., Sriram, S., ~~Eakin, A.E~~.	+	==Reference==
-		+	<ref group="xtra">PMID:024098982</ref><references group="xtra"/><references/>
-	~~Description~~: ~~Crystal structure of a topoisomerase ATP~~ inhibitor	+	[[Category: Basarab, G S.]]
		+	[[Category: Bist, S.]]
		+	[[Category: Boriack-Sjodin, P A.]]
		+	[[Category: Dangel, B.]]
		+	[[Category: Eakin, A E.]]
		+	[[Category: Illingsworth, R.]]
		+	[[Category: Manchester, J I.]]
		+	[[Category: Sherer, B A.]]
		+	[[Category: Sriram, S.]]
		+	[[Category: Uria-Nickelsen, M.]]
		+	[[Category: Antimicrobial]]
		+	[[Category: Atp binding]]
		+	[[Category: Atpase domain]]
		+	[[Category: Isomerase-isomerase inhibitor complex]]
		+	[[Category: Protein-inhibitor complex]]
		+	[[Category: Structure-based drug design]]
		+	[[Category: Virtual screen]]

OCA at 07:30, 29 September 2013

2013-09-29T07:30:35Z

←Older revision		Revision as of 07:30, 29 September 2013
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 4lp0 is ON HOLD	+	The entry 4lp0 is ON HOLD until sometime in the future

	Authors: Basarab, G.S., Manchester, J.I., Bist, S., Boriack-Sjodin, P.A., Dangel, B., Illingsworth, R., Uria-Nickelsen, M., Sherer, B.A., Sriram, S., Eakin, A.E.		Authors: Basarab, G.S., Manchester, J.I., Bist, S., Boriack-Sjodin, P.A., Dangel, B., Illingsworth, R., Uria-Nickelsen, M., Sherer, B.A., Sriram, S., Eakin, A.E.

	Description: Crystal structure of a topoisomerase ATP inhibitor		Description: Crystal structure of a topoisomerase ATP inhibitor

OCA: Protected "4lp0" [edit=sysop:move=sysop]

2013-07-24T12:30:30Z

Protected "4lp0" [edit=sysop:move=sysop]

←Older revision

Revision as of 12:30, 24 July 2013

OCA: New page: '''Unreleased structure''' The entry 4lp0 is ON HOLD Authors: Basarab, G.S., Manchester, J.I., Bist, S., Boriack-Sjodin, P.A., Dangel, B., Illingsworth, R., Uria-Nickelsen, M., Sherer, ...

2013-07-24T12:30:29Z

New page: '''Unreleased structure''' The entry 4lp0 is ON HOLD Authors: Basarab, G.S., Manchester, J.I., Bist, S., Boriack-Sjodin, P.A., Dangel, B., Illingsworth, R., Uria-Nickelsen, M., Sherer, ...

New page

'''Unreleased structure'''

The entry 4lp0 is ON HOLD

Authors: Basarab, G.S., Manchester, J.I., Bist, S., Boriack-Sjodin, P.A., Dangel, B., Illingsworth, R., Uria-Nickelsen, M., Sherer, B.A., Sriram, S., Eakin, A.E.

Description: Crystal structure of a topoisomerase ATP inhibitor